8-K: Milestone Pharma Secures $75M from Etripamil Royalty Sale

Milestone Pharmaceuticals Inc. announced the closing of its previously disclosed royalty sale agreement, receiving $75.0 million from RTW for U.S. etripamil sales royalties.

Summary

• Milestone Pharmaceuticals Inc. closed the sale of its royalty interest in etripamil to RTW Royalty I DAC, an affiliate of RTW Investments, LP.
• The company received a purchase price of $75.0 million from certain funds managed by RTW.
• The royalty interest pertains to tiered quarterly royalty payments on annual net product sales of etripamil in the United States.
• The original Purchase and Sale Agreement was entered into on March 27, 2023, and was subject to certain conditions, including U.S. Food and Drug Administration approval of etripamil.

Sentiment

Score: 7

Explanation: The filing reports the successful closing of a significant financing transaction, providing a substantial cash infusion to the company. While positive for immediate liquidity and non-dilutive, it represents the execution of a previously announced plan and involves foregoing future royalty income.

Positives

• The company received a significant cash infusion of $75.0 million, strengthening its financial position.
• This transaction represents a non-dilutive financing strategy, avoiding the issuance of new equity.
• The closing of the agreement indicates that the conditions for the sale, including potential FDA approval of etripamil, have been met or satisfied.

Negatives

• The company has foregone future tiered quarterly royalty payments on U.S. net product sales of etripamil, potentially limiting long-term revenue upside from the drug.

Risks

• The original agreement was contingent on U.S. Food and Drug Administration approval of etripamil, implying ongoing regulatory risk until full approval is confirmed and publicly announced.
• Future sales performance of etripamil in the United States will impact RTW's return on investment, but Milestone will no longer directly benefit from these specific royalty streams.

Future Outlook

The $75.0 million cash infusion provides Milestone Pharmaceuticals with significant capital, which is expected to support ongoing operations, development, and potential commercialization efforts for etripamil, contingent on its U.S. Food and Drug Administration approval.

Management Comments

• Milestone Pharmaceuticals Inc. has duly caused this report to be signed on its behalf by Amit Hasija, Chief Financial Officer and Principal Financial Officer.

Industry Context

Royalty monetization is a common non-dilutive financing strategy in the biotechnology and pharmaceutical industries, particularly for companies with promising drug candidates nearing regulatory approval. It allows companies to secure immediate capital for further development or commercialization without issuing new equity, while transferring future revenue streams to specialized royalty investors.

Stakeholder Impact

• Shareholders benefit from a strengthened balance sheet and reduced immediate financing risk, potentially supporting continued drug development without further equity dilution.
• The company gains significant capital to fund its strategic initiatives, including the potential commercialization of etripamil.

Next Steps

• Continued focus on the development and potential commercialization of etripamil, leveraging the newly acquired capital.

Key Dates

Recommendation

The closing of the $75.0 million royalty sale is a positive development, providing a substantial cash infusion and strengthening Milestone Pharmaceuticals' financial position without equity dilution. However, this was a previously disclosed and expected event. While it de-risks the balance sheet, it does not introduce new fundamental operational news or guidance that would significantly alter the long-term investment thesis for etripamil's success or failure. Investors should continue to hold, awaiting further updates on etripamil's regulatory status and commercialization plans.

Keywords

Milestone Pharmaceuticals, etripamil, royalty sale, RTW Investments, financing, pharmaceuticals, FDA approval, cash infusion, biotechnology